HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission.

Abstract
In the present study, we have conducted a meta-analysis comparing autologous bone marrow transplantation (ABMT) and intensive chemotherapy in adult acute myeloid leukemia (AML) patients in first remission. Combined results of the six appropriate randomised controlled studies indicate that ABMT had no advantage over chemotherapy or no further treatment concerning death rate (overall rate ratio (RR)-0.95, 95% CI, 0.81-1.11), while was superior to chemotherapy concerning event rate (overall RR--0.82, 95% CI, 0.71-0.94). In conclusion, ABMT did not improve survival but it improved event-free survival (EFS) when compared with chemotherapy or no further treatment in patients with AML in first complete remission.
AuthorsItai Levi, Itamar Grotto, Ronit Yerushalmi, Isaac Ben-Bassat, Ofer Shpilberg
JournalLeukemia research (Leuk Res) Vol. 28 Issue 6 Pg. 605-12 (Jun 2004) ISSN: 0145-2126 [Print] England
PMID15120937 (Publication Type: Comparative Study, Journal Article, Meta-Analysis)
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bone Marrow Transplantation
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Infant, Newborn
  • Leukemia, Myeloid (therapy)
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Remission Induction
  • Transplantation, Autologous
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: